Innobic (Hangzhou) Biopharmaceuticals Completes Nearly RMB 200 Million Series B Financing to Advance Off-the-Shelf NK Cell Therapies

Recently, Imbioray (Hangzhou) Biopharmaceutical Co., Ltd. ("Imbioray") successfully completed a nearly 200 million yuan Series B financing round. This round was led by Deep Intelligent Pharma Co., Ltd., with investments from renowned entrepreneur Shen Yousheng, Hainan Yuque Investment Co., Ltd., and Hangzhou Xiner Technology Co., Ltd., while ROBE CAPITAL served as the long-term financial advisor. The successful completion of this financing round not only signifies the capital market's high recognition of Imbioray's core technological strength and future development potential but also injects strong momentum into its continued efforts in the innovative cell therapy sector, accelerating the industrialization process of its core products and seizing the opportunity for industry leadership.

imbioray, as a company in the global off-the-shelf NK cell therapy field, has since its establishment focused on the development of innovative drugs for immunotherapy targeting advanced global oncology treatments, as well as immune-related diseases, chronic conditions, and CNS disorders. Relying on core technologies such as non-viral vector and non-gene-edited ACC-NK and tiNK, the company has built a rich and competitive product pipeline. Currently, several core products have successfully entered clinical stages, demonstrating strong technical capabilities and broad market potential.